EU approves Sanofi drug for chronic lung disease

"Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU," Sanofi said in a statement.

Blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (Courtesy Phots)